PharVision Advisers’s iRhythm Holdings IRTC Stock Holding History

PharVision Advisers’s Portfolio IRTC Stock Details IRTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,292	Closed	-$229K	–	374
2025 Q4	$229K	Buy	+1,292	New	+$229K	0.12%	448

Other funds holding IRTC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's IRTC Position: Q1 2026 in Review

PharVision Advisers sold out of iRhythm Holdings (IRTC) in Q1 2026, closing a stake of 1,292 shares — an estimated $229K sold.

PharVision Advisers first reported a position in IRTC in Q4 2025 and held it in 1 quarter. The position peaked at $229K in Q4 2025. 304 funds tracked by Wall St. Rank hold IRTC as of Q1 2026.

PharVision Advisers reported no remaining iRhythm Holdings position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 1,292 iRhythm Holdings shares in Q1 2026, an estimated $229K.
PharVision Advisers first reported a position in iRhythm Holdings in Q4 2025 and held it in 1 quarter.
PharVision Advisers's iRhythm Holdings position peaked at $229K in Q4 2025.
304 funds tracked by Wall St. Rank held iRhythm Holdings as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.